Company Encyclopedia
View More
name
Hezong Medicine Easy-To-Buy Pharmaceutical
300937.SZ
Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. provides omni-channel pharmaceutical distribution services in China. It is involved in pharmaceutical B2B e-commerce, production, wholesale, and retail businesses, as well as provides logistics services. It offers Western medicine, Chinese patent medicine, Chinese herbal medicine slices and Chinese medicinal materials, food and health food, medical devices and non-pharmaceuticals, and other categories.
91.20 B
300937.SZMarket value -Rank by Market Cap -/-

Financial Score

19/11/2025 Update
C
Drug RetailIndustry
Industry Ranking9/9
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-0.71%D
    • Profit Margin-0.14%D
    • Gross Margin11.61%D
  • Growth ScoreD
    • Revenue YoY-1.48%D
    • Net Profit YoY-125.44%E
    • Total Assets YoY10.09%B
    • Net Assets YoY-2.97%D
  • Cash ScoreE
    • Cash Flow Margin-73991.73%E
    • OCF YoY-1.48%D
  • Operating ScoreA
    • Turnover2.46A
  • Debt ScoreD
    • Gearing Ratio56.02%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Hezong Medicine Easy-To-Buy Pharmaceutical: Net profit loss of 742,100 yuan in the third quarter, a decrease of 140.42%

    Hezong Medicine Easy-To-Buy Pharmaceutical announced that its revenue for the third quarter was 1.085 billion yuan, a year-on-year increase of 7.41%; net profit loss was 742,100 yuan, a decrease of 140.42%. Revenue for the first three quarters was 3.242 billion yuan, a year-on-year increase of 0.21%; net profit loss was 8.3565 million yuan, a decrease of 159.98%

    Zhitong·
    SZ
    300937
    -2.83%
    Zhitong·
    SZ
    300937
    -2.83%

    The pharmaceutical commercial sector experiences a surge, China Meheco hits the daily limit up

    The pharmaceutical commercial sector experienced a surge, with China Meheco hitting the daily limit, followed by Liuyao Group, SYPM, SHKK, LBX, and Hezong Medicine Easy-To-Buy Pharmaceutical rising in tandem

    Zhitong·
    SH
    600056
    +0.09%
    SZ
    301017
    -3.04%
    SH
    600272
    +4.14%
    Zhitong·
    SH
    600056
    +0.09%
    SZ
    301017
    -3.04%
    SH
    600272
    +4.14%

    Hezong Medicine Easy-To-Buy Pharmaceutical: Net profit loss of 7.6144 million yuan in the first half of 2025

    Hezong Medicine Easy-To-Buy Pharmaceutical announced that in the first half of 2025, the operating revenue was 2.157 billion yuan, a year-on-year decrease of 3.06%. The net profit loss was 7.6144 million yuan, compared to a net profit of 12.0957 million yuan in the same period last year

    Zhitong·
    SZ
    300937
    -2.83%
    Zhitong·
    SZ
    300937
    -2.83%

    Hezong Medicine Easy-To-Buy Pharmaceutical establishes a subsidiary, Shutan Artificial Intelligence

    Hezong Medicine Easy-To-Buy Pharmaceutical has established a wholly-owned subsidiary, Shutan Artificial Intelligence Technology Co., Ltd., with a registered capital of 10 million yuan, aimed at responding to the digital economy development policy. The company will integrate resources such as digital supply chains and intelligent procurement and sales systems, using AI, big data, and other technologies to build a SaaS digital comprehensive service platform, promoting the technological research and application of industry data resources

    Zhitong·
    SZ
    300937
    -2.83%
    Zhitong·
    SZ
    300937
    -2.83%

    Hezong Medicine Easy-To-Buy Pharmaceutical and others invest to establish an artificial intelligence technology company

    According to the Qichacha APP, recently, Sichuan Shutan Artificial Intelligence Technology Co., Ltd. was established with a registered capital of 10 million yuan. The business scope includes: first-class value-added telecommunications services; second-class value-added telecommunications services; internet information services for pharmaceuticals; internet information services for medical devices, etc. Qichacha's equity penetration shows that the company is jointly held by Sichuan Hezong Medicine Easy-To-Buy Technology Group Co., Ltd. and others under Hezong Medicine Easy-To-Buy

    Zhitong·
    SZ
    300937
    -2.83%
    Zhitong·
    SZ
    300937
    -2.83%